Changes in medication preceding out-of-hospital cardiac arrest where resuscitation was attempted

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 6, 2014, Pages 497-503

  Holmgren, Christina M ^a,b   Abdon, Nils J ^c   Bergfeldt, Lennart B ^a   Edvardsson, Nils G ^a   Herlitz, Johan D ^d   Karlsson, Thomas ^a   Svensson, Leif G ^e   Astrand, Bengt H ^f  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b RYHOV COUNTY HOSPITAL   (Sweden)

^c Hudiksvall Hospital   (Sweden)

^d UNIVERSITY OF BORÅS   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f LINNAEUS UNIVERSITY   (Sweden)

Author keywords

Medication; Out of hospital cardiac arrest; QT prolongation; Torsade de pointes

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; BISOPROLOL; CIPROFLOXACIN; CITALOPRAM; CLOPIDOGREL; DICLOFENAC; DOXYCYCLINE; ENALAPRIL; EXPECTORANT AGENT; FERROUS SULFATE; FUROSEMIDE; GLYCERYL TRINITRATE; LACTULOSE; MACROGOL; METOPROLOL; OMEPRAZOLE; OPIATE DERIVATIVE; OXAZEPAM; PARACETAMOL; PREDNISOLONE; SALBUTAMOL; SIMVASTATIN; SPIRONOLACTONE; TERBUTALINE; TRAMADOL; UNINDEXED DRUG; UREA; WARFARIN; ZOPICLONE;

ADULT; AGED; ARTICLE; FEMALE; HEART RHYTHM; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUT OF HOSPITAL CARDIAC ARREST; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; REGISTER; RESUSCITATION; CHEMICALLY INDUCED; EPIDEMIOLOGY; OUT-OF-HOSPITAL CARDIAC ARREST; SWEDEN; TIME; TRENDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARDIOPULMONARY RESUSCITATION; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OUT-OF-HOSPITAL CARDIAC ARREST; REGISTRIES; SWEDEN; TIME FACTORS;

EID: 84902257272     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000073     Document Type: Article

References (31)

1. Kong MH, Fonarow GC, Peterson ED, et al. Systematic review of the incidence of sudden cardiac death in the United States. J Am Coll Cardiol. 2011;57:794-801.
2. Atwood C, Eisenberg MS, Herlitz J, et al. Incidence of EMS-treated outof-hospital cardiac arrest in Europe. Resuscitation. 2005;67:75-80.
3. The Swedish Cardiac Arrest Register (Svenska Hjärtstoppsregistret). Available at: www.hlr.nu. Accessed November 1, 2011.
4. Stromsoe A, Svensson L, Axelsson AB, et al. Validity of reported data in the Swedish Cardiac Arrest Register in selected parts in Sweden. Resuscitation. 2013; 84: 952-956.
5. Narang P, El-Refai M, Parlapalli R, et al. Antipsychotic drugs: sudden cardiac death among elderly patients. Psychiatry (Edgmont). 2010;7:25-29.
6. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89:1363-1372.
7. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000;47:219-233.
8. Weeke P, Folke F, Gislason GH, et al. Pharmacotherapy and hospital admissions before out-of-hospital cardiac arrest: a nationwide study. Resuscitation. 2010;81:1657-1663.
9. De Bruin ML, Langendijk PN, Koopmans RP, et al. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol. 2007;63:216-223.
10. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726-735.
11. ATC codes. Available at: http://www.whocc.no/atc-ddd-publications/ guidelines/. Accessed November 1, 2011.
12. The Prescribed Drug Register, the National Board of Health and Wellfare. Available at: www.socialstyrelsen.se/statistik/statistikdatabas/lakemedel. Accessed October 10, 2013.
13. Arizona C. Available at: www.qtdrugs.org. Accessed November 1, 2011.
14. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011; 86: 304-314.
15. Glader EL, Sjolander M, Eriksson M, et al. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke. 2010;41:397-401.
16. Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): casecontrol study. Lancet. 2004;364:953-962.
17. Rugulies R. Depression as a predictor for coronary heart disease. a review and meta-analysis. Am J Prev Med. 2002;23:51-61.
18. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-235.
19. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161-1167.
20. Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med. 2004;164:1293-1297.
21. Astrom-Lilja C, Odeberg JM, Ekman E, et al. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2008;17:587-592.
22. Mehta A, Mehta D, Loganathan J, et al. Clopidogrel with proton pump inhibitors: safe or not? Clin Cardiol. 2011;34:528-531.
23. Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690.
24. Olsen AM, Fosbol EL, Lindhardsen J, et al. Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study. Circulation. 2012;126:1955-1963.
25. Sejersted OM, Sjogaard G. Dynamics and consequences of potassium shifts in skeletal muscle and heart during exercise. Physiol Rev. 2000;80: 1411-1481.
26. Insulander P, Juhlin-Dannfelt A, Freyschuss U, et al. Electrophysiologic effects of salbutamol, a beta2-selective agonist. J Cardiovasc Electrophysiol. 2004;15:316-322.
27. Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol. 2004;15:475-495.
28. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-1022.
29. De Ponti F, Poluzzi E, Vaccheri A, et al. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. Br J Clin Pharmacol. 2002;54:171-177.
30. Allen LaPointe NM, Curtis LH, Chan KA, et al. Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf. 2006; 15:361-368.
31. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol. 2006;46:498-507.